The M. D. Anderson Myeloma SPORE Career Development Program (CDP) has the following objectives: 1. Recruit and train physicians, scientists, and senior postdoctoral fellows to become outstanding translational investigators in myeloma research. 2. Establish a Structure for Project Identification and Selection. Publicize the availability of start-up funding for pilot projects in myeloma translational research. Develop a peer-review mechanism to select competing proposals for funding using internal and external reviewers. Develop specific criteria for selection of projects for funding for use by the reviewers. The SPORE Administrative Core plays a major role in this. Identify projects that are innovative and have significant potential for improving treatment outcome of myeloma. The expertise of SPORE Pis, Project Leaders, Co-Investigators, and the scientific advisory board will be sought to achieve this goal. 3. Provide funding, resources, and encourage SPORE Collaborations. Provide development funding (usually in the amount of-$50,000) for projects in the M. D. Anderson Myeloma SPORE and for scientists at other institutions outside the SPORE environment. Encourage collaborations among scientists in the SPORE and with scientists outside the SPORE environment that will help investigators reach their objectives. Connect young investigators with other myeloma basic and clinical investigators at M. D. Anderson and at other SPORE institutions. The SPORE PI and Co-PI will work with investigators to define translational research goals and steps required to effectively and rapidly translate the research into application in humans. The CDP will facilitate access to SPORE Cores needed to reach these goals - Myeloma Tissue, Clinical Trials, Animal Models, Bioinformatics and Biostatistics, and GMP laboratory Cores. 4. Provide Mentorship for Career Development Awardees. Develop a mechanism for closely mentoring and monitoring the work ofthe Career Development Awardees to help achieve their translational research goals. Require Career Developmental Project investigators to give official presentations of their work at the regular monthly SPORE meetings as well as annual written reports. Provide expert mentors in myeloma translational research for the Career Development Projects. Review and help Career Development Project Investigators prepare their results for presentation and encourage presentation at inter-SPORE meetings, such as at the annual SPORE meeting. 5. Provide Assistance and Guidance For Obtaining Independent Peer Reviewed Funding. Require, with assistance, preparation of other peer-reviewed funding applications, such as R21 and Foundation grants, and help with grant draft review, and provide letters of support for these applications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Xia, Yi; Jeffrey Medeiros, L; Young, Ken H (2016) Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 1865:58-71
Xu-Monette, Zijun Y; Zhang, Shanxiang; Li, Xin et al. (2016) p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY) 8:345-65
Kanagal-Shamanna, Rashmi; Xu-Monette, Zijun Y; Miranda, Roberto N et al. (2016) Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology 68:482-91
Cao, Xin; Medeiros, L Jeffrey; Xia, Yi et al. (2016) Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 57:1104-13
Zhang, Xing-Ding; Baladandayuthapani, Veerabhadran; Lin, Heather et al. (2016) Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29:639-52
Zhou, Liang; Chen, Shuang; Zhang, Yu et al. (2016) The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 127:2219-30
Ye, Qing; Xu-Monette, Zijun Y; Tzankov, Alexandar et al. (2016) Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget 7:2401-16
Tang, Jinle; Li, Jialu; Zhu, Xuejun et al. (2016) Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget 7:34070-83
Shah, Jatin J; Jakubowiak, Andrzej J; O'Connor, Owen A et al. (2016) Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res 22:34-43
de Winde, Charlotte M; Veenbergen, Sharon; Young, Ken H et al. (2016) Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest 126:653-66

Showing the most recent 10 out of 169 publications